call 1800 257 600 email [email protected]

MUTYH-Associated Polyposis (MAP)

MUTYH-associated polyposis (MAP) is a rare genetic condition that increases the risk of developing certain types of cancer, most notably colon cancer. It is caused by an alteration in the mutY DNA glycosylase (MUTYH) gene, which is involved in DNA damage repair. People with MAP often develop between 10-100 polyps within the colon, however it can also develop in areas of the small intestine.

Familial cancer syndromes, also known as hereditary cancer syndromes, are rare conditions that cause an increased risk of cancer as the result of inherited genetic mutations in certain cancer-related genes. They can affect both adults and children, however they generally develop in people at a younger age than normal. While familial cancer syndromes are not classified as cancer, they are equally as severe and can be life-threatening as they are associated with the development of various tumours throughout the body. Having a familial cancer syndrome does not guarantee the development of cancer, however the risk of developing cancer is higher than those who do not have a familial cancer syndrome.

MAP is generally diagnosed equally among the sexes, and is often diagnosed between the ages of 40-60. However, anyone can develop this disease.

MAP is most commonly associated with the development of colorectal cancers, however it has also been linked to other types of tumours. Some examples include:

The following tumours may also have an increased incidence in people with MAP, however more research is needed to confirm:

Treatment

When cancers are detected, they are staged and graded based on size, metastasis, and how the cancer cells look under the microscope. Staging and grading helps your doctors determine the best treatment for you. However, each patient with MAP will present with a unique disease behaviour, with varying tumour locations and symptoms. As such, there is no one treatment method that will work for everyone, and there is no standard staging system for this disease. Instead of staging and grading, your doctor will recommend a treatment plan based on the following factors:

  • Type of tumours present.
  • Whether the tumours are malignant (cancerous) or benign (non-cancerous).
  • Tumour location.
  • Whether or not malignant tumours have metastasised.
  • Your age.
  • General health.
  • Your treatment preferences.

Your doctor may also recommend genetic testing, which analyses your tumour DNA and can help determine which treatment has the greatest chance of success. They will then discuss the most appropriate treatment option for you.

Treatment options for tumours associated with MAP may include:

  • Surgery to remove as much of the tumour(s) as possible – this will vary based on location.
  • Chemotherapy.
  • Radiation therapy.
  • Clinical trials.
  • Palliative care.

Cancer Screening

Once a diagnosis of MAP has been confirmed, implementing a targeted screening plan becomes essential due to the increased risk of developing certain cancers.  The content of this plan will vary from person to person based on the genetic mutation involved, your family’s history of cancer and the types of cancers that may be present. It will also outline the routine tests you should have and how regularly you should have them.  Some recommendations for MAP may include:

  • Annual physical examination.
  • Colonoscopy every 1-2 years starting at age 25-30.
  • Gastroscopy starting at age 30-35 (suggested frequency in literature ranges from three months to four years).
  • Annual thyroid ultrasound in patients at risk of thyroid cancer.

Screening options for MAP may evolve as new technologies are developed and our understanding of the condition grows. It is essential to discuss your individual circumstances with your healthcare team to determine the most appropriate screening plan for you.

Risk factors

MAP is caused by a genetic mutation in the mutY DNA glycosylase (MUTYH) gene, which is involved in DNA damage repair. It is an autosomal recessive disorder, which means that you have to inherit one gene with the mutation from both parents in order to develop the condition. If both of parents carry the gene, there is a one in four chance of a child having the condition.

Symptoms

The symptoms of MAP often vary by the type(s) of tumours present. General symptoms of MAP may include:

  • The presence of 10 to 100 colorectal polyps.
  • Abdominal pain and/or discomfort.
  • Changes in bowel movements, potentially including:
    • Diarrhoea.
    • Constipation.
    • Feeling of incomplete bowel movement.
    • Thin bowel stools.
    • Blood in stools.
  • Rectal bleeding.
  • Unexplained weight loss/loss of appetite.
  • Fatigue.
  • Anaemia.
  • Nausea and/or vomiting.

Symptoms related to specific tumours can be found on our knowledgebase.

Not everyone with the symptoms above will have cancer, but see your general practitioner (GP) if you are concerned.

Diagnosis

If your doctor suspects you have tumours associated with MAP they may order some of the following tests to confirm the diagnosis and refer you to a specialist for treatment. The tests required for diagnosis will often vary based on the symptoms present, and where the tumour(s) are suspected to be located.

  • Physical examination.
  • Genetic testing.
  • Pelvic examination.
  • Digital rectal examination (DRE).
  • Blood tests.
  • Imaging tests, potentially including:
    • Ultrasound.
    • MRI (magnetic resonance imaging).
    • CT (computed tomography) scan.
  • Exploratory procedures, such as:
    • Colonoscopy.
    • Flexible sigmoidoscopy.
    • Other types of endoscopy as indicated.
  • Biopsy.

References

Keep up with Rare Cancers Australia

Inside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.